SCIENTIFIC REPORTS

OPEN

Author Correction: Development of new method to enrich human iPSC-derived renal progenitors using cell surface markers

Azusa Hoshina¹, Tatsuya Kawamoto², Shin-Ichi Sueta¹, Shin-Ichi Mae¹, Toshikazu Araoka¹, Hiromi Tanaka¹, Yasunori Sato³, Yukiko Yamagishi² & Kenji Osafune¹

Correction to: *Scientific Reports* <https://doi.org/10.1038/s41598-018-24714-3>, published online 23 April 2018

In Figure 2C, the qRT-PCR data for *SIX2* and *SALL1* were miscalculated. As a result, the graphs of *SIX2* and *SALL1* expression are incorrect. The correct Figure 2 appears below as Figure 1.

Additionally in Figure 4C, the qRT-PCR data for *Col4a1* were also miscalculated. As a result, the graph of *Col4a1* expression is incorrect. The correct Figure 4 appears below as Figure 2.

¹Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan. ²Drug Discovery Research, Astellas Pharma Inc, Tsukuba, Ibaraki, Japan. ³Department of Global Clinical Research, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Japan. Correspondence and requests for materials should be addressed to T.K. (email: tatsuya.kawamoto@astellas.com) or K.O. (email: osafu@cira.kyoto-u.ac.jp)

Figure 1. The expression of renal lineage markers in $CD9^{-}CD140a^{+}CD140b^{+}CD271^{+}$ cells isolated from hiPSC differentiation culture. **(A)** Anti-GFP (OSR1), SIX2 and HOXD11 immunostaining images of the cells before isolation (upper panels) and isolated $CD9^{-}CD140a^{+}CD140b^{+}CD271^{+}$ cells (lower panels) on culture days 28 (SIX2) and 30 (OSR1 and HOXD11). Representative images from three independent experiments are shown. Scale bars, 100 μ m. **(B)** The induction rates of SIX2+ cells in day 28 cells before and after isolation. The data from three randomly chosen fields are presented as the mean $\pm$ SE ($n = 3$). **(C,D)** qRT-PCR analyses of gene expressions in day 28 cells before and after isolation for markers of nephron progenitors **(C)** and undifferentiated cells **(D)**. The data from three independent experiments are presented as the mean $\pm$ SE ($n = 3$). GAPDH was used as an internal control, and the relative expression levels were normalized to those of day 28 cells before isolation **(C)** and hiPSCs **(D)**. ITGA8, integrin alpha 8; CDH11, cadherin 11.

Figure 2. The evaluation of kidney fibrosis after cell therapy using hiPSC-derived CD9⁺CD140a⁺CD140b⁺CD271⁺ cells in mouse acute kidney injury (AKI) models (A) Representative images of host mouse kidney sections stained with anti- α smooth muscle actin (α -SMA) immunostaining and Masson's trichrome (MT) and Sirius red (SR) stainings in saline- (upper panels) or CD9⁺CD140a⁺CD140b⁺CD271⁺ cell (iPSC-RP, lower panels)-treated groups. The boxed areas are magnified and displayed in the right panels. Scale bars, 500 μ m in the panel to the farthest left and 100 μ m in the others. (B) Quantitative analyses of kidney fibrosis areas by anti- α -SMA immunostaining and MT and SR stainings in the host kidneys on day 12 after I/R injury (n = 4). Statistical significance: *P < 0.05 vs. saline after multiple testing adjustment. (C) qRT-PCR analyses of gene expression in the host kidneys on day 12 after I/R injury for the markers of kidney fibrosis (n = 4). Statistical significance: *P < 0.05 vs. saline after multiple testing adjustment. *Fsp1*, Fibroblast-specific protein 1; *Col4a1*, alpha-1 subunit of collagen type IV, NS, not significant.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019